Tempest Therapeutics, Inc. (OVAS) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Operating activities:
Net loss	-35.7	-28.3	-19.2	-44.6	-27.2
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	0.6	0.4	0.3	0.1	0.0
Stock-based compensation expense	1.6	1.1	0.5	4.3	1.4	6.9	9.2	19.3
Changes in operating assets and liabilities:
Prepaid expenses and other assets	0.9	-0.2	0.4	-0.7	-2.5	0.9	0.9	-1.1
Accounts payable	0.0	-0.2	-0.6	-0.5	0.3	0.1	-1.2	-0.2
Accrued expenses and other liabilities	1.7	0.7	-0.2	0.3	3.2	-5.8	4.8	0.8
Interest payable	-0.3	0.1
Operating lease liabilities	-1.5	-1.0
Cash used in operating activities	-31.1	-26.0	-19.0	-41.2	-23.6	-45.6	-61.7	-50.3

Investing activities:
Purchase of property and equipment	-0.6	-0.1	-0.1	-0.4	0.0	-0.2	-2.6	-5.2
Cash used in investing activities	-0.6	-0.1	0.0	4.0	1.9	17.3	8.3	-38.3

Financing activities:
Proceeds from the issuance of common stock, net of issuance costs	8.9	33.4		26.7	38.8		53.9	124.1
Proceeds from the issuance of pre-funded warrants, net of issuance costs	7.3
Cash provided by financing activities	11.4	59.1	34.6	26.9	77.7		54.1	125.4

Supplemental disclosure of cash flow information:
Cash paid for interest	1.5	1.0
Cash paid for income taxes	0.0
Non-cash operating activities:
Lease modification	0.9
Non-cash investing activities:
Property and equipment in accounts payable	0.1	0.1				0.0	0.1	1.0